Biomarkers (BMKs) have become fundamental tools in drug development, accelerating and optimizing targeted therapeutic innovation. As a bioanalytical CRO with over 15 years of experience in biomarker analysis, we’ve seen firsthand how the strategic integration of biomarkers can accelerate drug programs, help meet evolving regulatory standards,…

From initial receipt to final disposition, sample integrity, traceability, and compliance are the foundation of our bioanalytical operations. We’re taking you behind the scenes to follow the journey of a sample through our facility.  Here’s a detailed look at each stage in the lifecycle of a study sample at KCAS…

KCAS Bio participated in the AAPS National Biotechnology Conference (NBC), held from May 4 to May 7, 2025, in Boston. It was a productive event that allowed us to connect with sponsors, exchange ideas with peers, and present our latest work in bioanalytical science. Our experts…

In drug development, the journey from target identification to clinical candidate selection involves a series of critical steps, including compound screening, lead optimization, and pre-clinical testing. Each stage helps narrow the pool of potential therapeutics, with the goal of identifying the most promising candidates for clinical evaluation. Given the time,…

At KCAS Bio, we offer expert flow cytometry services designed to support the evolving bioanalytical needs of immunology and biomarker projects for drug development. Whether you’re working in preclinical or clinical settings, our validated off-the-shelf panels save time, reduce risk, and deliver high-quality, reproducible data you can trust. Extensive Portfolio…

KCAS Bio offers a wide range of biomarker services, from cell-based to soluble biomarker analysis, including ligand binding assays (LBA), across a variety of matrix types.  Soluble biomarker analysis can be achieved on multiple platforms depending on factors such as sample type, required sensitivity, and whether multiplexing is…